GlassScriptPhysician profile
Joseph W Kaiser
NPI 1295730471
$3,936.90
in general payments reported to CMS, 2019-2025
33 companies · $634 in 2025
The $634 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $222 · 2021: $462 · 2022: $604 · 2023: $588 · 2024: $620 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,825 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.74 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $442.21 | 2019-2025 | Tavneos, Krystexxa, Otezla |
| Astrazeneca Pharmaceuticals LP | $435.32 | 2019-2025 | Farxiga, Breztri |
| Otsuka America Pharmaceutical, INC. | $431.38 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $355.50 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Aurinia Pharma U.S., INC. | $317.95 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $235.52 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $170.15 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $167.18 | 2020-2025 | Acthar |
| Calliditas Therapeutics US INC. | $156.62 | 2022-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $130.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $123.97 | 2022-2025 | Benlysta |
| Takeda Pharmaceuticals U.S.A., INC. | $118.98 | 2020-2023 | Gattex |
| Genzyme Corporation | $118.06 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.40 | 2021-2025 | Jardiance |
| Akebia Therapeutics INC | $66.77 | 2019-2024 | Auryxia, Vafseo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $62.68 | 2020-2023 | Veltassa, Korsuva |
| Mallinckrodt Enterprises LLC | $59.89 | 2019 | |
| Novo Nordisk INC | $54.41 | 2021 | |
| Horizon Therapeutics Plc | $42.64 | 2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.63 | 2022-2024 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.72 | 2019-2022 | |
| Pfizer INC. | $38.29 | 2022 | |
| Ardelyx, INC. | $35.80 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $29.13 | 2023 | Oxlumo |
| Xeris Pharmaceuticals, INC. | $28.41 | 2025 | Keveyis |
| Ani Pharmaceuticals, INC. | $26.00 | 2025 | Purified Cortrophin Gel |
| Cormedix INC. | $24.51 | 2024 | Defencath |
| Abbott Laboratories | $17.49 | 2021 | |
| Apellis Pharmaceuticals, INC. | $16.54 | 2025 | Empaveli |
| Bardy Diagnostics, INC. | $14.55 | 2022 | |
| Amarin Pharma, INC. | $12.80 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.58 | 2021 | |
| Bard Peripheral Vascular, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Kaiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.